小剂量利妥昔单抗治疗系统性红斑狼疮的临床观察  

Clinical observation of low-dose rituximab in patients with systemic lupus erythematosus

作　　者：王春燕[1] 张娟[1] 刘媛媛[1] 王轶[1] 王丽萍[1] 张莉[1] 

机构地区：[1]兰州大学第二医院风湿免疫科,730030

出　　处：《中华风湿病学杂志》2011年第8期537-540,共4页Chinese Journal of Rheumatology

摘　　要：目的评价小剂量利妥昔单抗治疗系统性红斑狼疮（SLE）的疗效和安全性。方法对既往激素和多种免疫抑制剂治疗无效或复发的10例SLE患者，予利妥昔单抗100mg，使用4次，同时仅联合使用激素，观察疗效和不良反应。结果利妥昔单抗对狼疮肾炎、神经精神性狼疮、顽固性血小板减少以及自身免疫性溶血性贫血均显示有良好的疗效，且起效迅速。10例患者中仅1例出现了泌尿系感染，1例在首剂利妥昔单抗治疗1周后猝死，但不能确定死亡原因与利妥昔单抗相关。结论小剂量利妥昔单抗治疗SLE有良好的疗效和安全性，并且降低了治疗费用。Objective To assess the clinical efficacy and safety of low-dose rituximab in patients with systemic lupus erythematosus （SLE）. Methods Patients with SLE, refractory to conventional glucocortieoid and immunosuppressive drugs, were treated with low-dose rituximab （100 mg×4） in combination with glucocorticoid. Their responses to treatment as well as outcome were investigated. Results Treatment with rituximab had better efficacy and faster response for lupus nephritis, neuropsychiatric SLE, autoimmune hemolytic anemia and thrombocytopenia. Only one ease presented with secondary urinary infection, another one died one week later after the first dose of rituximab treatment, but the association between the death and rituximab could not be determined. Conclusion Treatment of SLE with low-dose rituximab has shown that it is effective and safe, and cost is low.

关 键 词：红斑狼疮 系统性 治疗结果 利妥昔单抗 不良反应 

分 类 号：R593.241[医药卫生—内科学]